Dawn Lee
Associate Professor of Health Economics and Health Policy
D.Lee7@exeter.ac.uk
Overview
Dawn is Associate Professor of Health Economics and Health Policy, working with the Peninsula Technology Assessment Group (PenTAG), one of 11 research units in the UK providing expert advice on the clinical and cost-effectiveness of new drugs to the National Institute of Health and Care Excellence (NICE).
Dawn joined PenTAG / Exeter University in Sept 2022 following over 15 years in economic consultancy where she worked most recent as the Chief Scientific Officer for a medium sized health economics consultancy (Lumanity; formerly BresMed). She is a health economic modeler who has conducted over 50 UK Health Technology Assessment submissions and worked in over 30 countries globally, a member of NICE’s interventional procedures advisory committee (IPAC) and the R for HTA group. Dawn’s key project achievements include representing manufacturers at ~30 HTA Committee meetings, working on the first ever immune-oncology submission to NICE (TA268), first ever PD-1 submission to NICE (TA384) and a considerable number following this and the first ITC accepted by G-BA.
Dawn’s main research interests are oncology modelling; particularly immune-oncology and therefore flexible survival modelling and the incorporation of external data within extrapolations, structured expert elicitation and improving diagnostic pathways.
Qualifications
- MSc Health Economics and Decision Modelling
- MMath Mathematics
Research
Research interests
Dawn’s main research interests are:
- Oncology modelling; particularly immune oncology and the various issues that stem from this including flexible survival modelling, incorporation of external data within extrapolations, methods for assessment of tumor agnostic indications, issues around combination therapies
- Structured expert elicitation (where she is currently working on development of open-source materials with York University with the aim of facilitating greater uptake)
- Increasing uptake of more efficient software for health economic modelling. Ideated and oversaw the development of intRfac : an end-to-end modelling solution using R / R-SHINY to increase the efficiency of model development and ease of quality control.https://bresmed-intrface-hypothetical-car-t-model.shinyapps.io/IntRface_Model-PharmacoEconomics/
- Next gen HTx: patient-centered, societally oriented, real-time decision making on access to and reimbursement for health technologies
- Improving diagnostic pathways
Publications
Journal articles
Burke C, Crossan C, Tyas E, Hemstock M, Lee D, Bowditch S (2024). A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales. PharmacoEconomics - open Abstract.
Lee D, Burns D, Wilson E (2024). Correction: NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. Pharmacoecon Open Author URL.
Hart RJ, Hassan F, Alulis S, Patterson KW, Barthelmes JN, Boer JH, Lee D (2024). Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes. Adv Ther, 41(5), 2010-2027. Abstract. Author URL.
Lee D, Burns D, Wilson E (2024). NICE's Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances. Pharmacoecon Open Author URL.
Trigg LA, Melendez-Torres GJ, Abdelsabour A, Lee D (2024). Treatment Effect Waning Assumptions: a Review of National Institute of Health and Care Excellence Technology Appraisals. Value Health Abstract. Author URL.
Lee D, McNamara S (2023). Dynamic Mortality Modeling: Incorporating Predictions of Future General Population Mortality into Cost-Effectiveness Analysis. Value in Health, 26(8), 1145-1150.
Lee D, McCarthy G, Saeed O, Allen R, Malottki K, Chandler F (2023). The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products. PharmacoEconomics - Open, 7(2), 175-187. Abstract.
Aguiar-Ibáñez R, Hardern C, van Hees F, Lee D, Patel A, Chhabra N, Baluni G, Amonkar M, Lai Y, Xu R, et al (2022). Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Journal of medical economics, 25(1), 469-480. Abstract.
Grant TS, Burns D, Kiff C, Lee D (2020). A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity. PharmacoEconomics, 38(4), 385-395. Abstract.
Kirkham FJ, Vigevano F, Raspall-Chaure M, Wilken B, Lee D, Le Reun C, Werner-Kiechle T, Lagae L (2020). Health-related quality of life and the burden of prolonged seizures in noninstitutionalized children with epilepsy. Epilepsy & Behavior, 102, 106340-106340.
Uyl‐de Groot CA, Ramsden R, Lee D, Boersma J, Zweegman S, Dhanasiri S (2020). Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: a pharmaco‐economic assessment. European Journal of Haematology, 105(5), 635-645. Abstract.
Hart R, Burns D, Ramaekers B, Ren S, Gladwell D, Sullivan W, Davison N, Saunders O, Sly I, Cain T, et al (2020). R and Shiny for Cost-Effectiveness Analyses: Why and When? a Hypothetical Case Study. Pharmacoeconomics, 38(7), 765-776. Abstract. Author URL.
Batteson R, Hart R, Hemstock M, Gooden K, Kotapati S, Roze S, Lee D, Amadi A (2019). Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. PharmacoEconomics - Open, 4(2), 343-351.
Bullement A, Meng Y, Cooper M, Lee D, Harding TL, O'Regan C, Aguiar-Ibanez R (2018). A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?. Journal of medical economics, 22(3), 205-214. Abstract.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, et al (2018). Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? the Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics - Open, 3(1), 43-54.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, et al (2018). Correction to: can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? the Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England. PharmacoEconomics - Open, 3(1), 127-127.
Vigevano F, Kirkham FJ, Wilken B, Raspall-Chaure M, Grebla R, Lee D, Werner-Kiechle T, Lagae L (2018). Effect of rescue medication on seizure duration in non-institutionalized children with epilepsy. European Journal of Paediatric Neurology, 22(1), 56-63.
Lee D, Brereton N, Dhanasiri S, Kulasekararaj A (2018). The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q. PharmacoEconomics - Open, 3(3), 351-358.
Meng Y, Hertel N, Ellis J, Morais E, Johnson H, Philips Z, Roskell N, Walker A, Lee D (2018). The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. The European Journal of Health Economics, 19(8), 1163-1172.
van Keep M, Gairy K, Seshagiri D, Thilakarathne P, Lee D (2016). Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma. BMC Cancer, 16(1).
Athanasakis K, Bilitou A, Lee D, Karampli E, Karavidas A, Parissis J, Sykara G, Kyriopoulos J (2016). Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece. ClinicoEconomics and Outcomes Research, Volume 8, 583-590.
Lee D, Porter J, Hertel N, Hatswell AJ, Briggs A (2016). Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. BioDrugs, 30(4), 307-319.
Hatswell AJ, Porter J, Lee D, Hertel N, Latimer NR (2016). The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight. Value in Health, 19(8), 1055-1058.
Borg S, Nahi H, Hansson M, Lee D, Elvidge J, Persson U (2015). Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. Acta Oncologica, 55(5), 554-560.
Gooding S, Lau I-J, Sheikh M, Roberts P, Wong J, Dickens E, Bullement A, Elvidge J, Lee D, Ramasamy K, et al (2015). Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. PLOS ONE, 10(9), e0136207-e0136207.
Lee D, Nielsen SK, van Keep M, Andersson F, Greene D (2015). Quality of Life Improvement in Patients Treated with Degarelix versus Leuprorelin for Advanced Prostate Cancer. Journal of Urology, 193(3), 839-846.
Larkin J, Hatswell AJ, Nathan P, Lebmeier M, Lee D (2015). The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLOS ONE, 10(12), e0145524-e0145524.
Lee DC, Gladwell D, Hatswell AJ, Porter J, Brereton N, Tate E, Saunders AL (2014). A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe. Health Economics Review, 4(1).
Lee D, Porter J, Gladwell D, Brereton N, Nielsen SK (2014). A cost–utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom. Journal of Medical Economics, 17(4), 233-247.
Lee D, Wilson K, Akehurst R, Cowie MR, Zannad F, Krum H, van Veldhuisen DJ, Vincent J, Pitt B, McMurray JJV, et al (2014). Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms. Heart, 100(21), 1681-1687.
Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, et al (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the <scp>MM</scp>‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology, 168(6), 820-823. Abstract.
Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M, Lee D (2014). Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12(1).
Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N (2013). Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland. Applied Health Economics and Health Policy, 11(5), 457-469.
Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N (2013). Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland. Applied Health Economics and Health Policy, 11(6), 687-687.
Lee D, Gladwell D, Batty AJ, Brereton N, Tate E (2013). The Cost Effectiveness of Licensed Oromucosal Midazolam (Buccolam®) for the Treatment of Children Experiencing Acute Epileptic Seizures: an Approach When Trial Evidence is Limited. Pediatric Drugs, 15(2), 151-162.
Conferences
Saunders O, Gregory J, Lee D, Farrell J (2016). LENALIDOMIDE FOR TREATING MULTIPLE MYELOMA AFTER 1 PRIOR TREATMENT; AN APPLICATION OF MULTI-STATE MARKOV MODELLING FOR THE EXTRAPOLATION OF PATIENT LEVEL SURVIVAL DATA. Author URL.
